Malignant gliomas are primary tumors of the central nervous system characterized by diffuse infiltration into the brain and a high recurrence rate. Advances in comprehensive genomic studies have provided unprecedented insight into the genetic and molecular heterogeneity of these tumors and refined our understanding of their evolution from low to high grade. However, similar levels of phenotypic characterization are indispensable to understanding the complexity of malignant gliomas.
| INTRODUCTION
Malignant gliomas are primary tumors that arise in the central nervous system. They are characterized clinically by progression from low to higher malignancy grades and by a response to a limited range of therapies. Biologically, their malignancy is the result in part of a high level of heterogeneity and of diffuse infiltration into normal brain tissue. Our understanding of the genetic makeup and molecular biology of malignant gliomas has seen great advances over the last few years. Progress in genomics, epigenomics, and data-mining is revealing previously unknown characteristics of these tumors. The
Cancer Genome Atlas study and several subsequent studies have thus characterized their patterns of somatic mutations, genome-wide DNA copy number alterations, and DNA methylation status. 1, 2 As a result of these findings, the World Health Organization classification of gliomas was revised to add a layer of molecular information to the classical pathology-based system. 3 Furthermore, biodata portals now offer access to large international databases of such findings that allows researchers to verify the expression of their molecule of interest, analyze prognosis, and integrate clinical, genomics, and transcriptomics data. 4 However, high-grade gliomas are heterogeneous, not only at the genetic level but at the cellular level. An equally detailed phenotypic characterization of these tumors and the linking of genomic landscapes to appropriate phenotypes will also be indispensable for the translation of preclinical knowledge into therapeutic strategies. Pertaining largely to cellular biology, questions regarding the cell of origin for gliomas and their diffuse infiltration into the brain parenchyma can be investigated only in animal models.
For more than 50 years, animal models have increased our understanding of human disease and have been instrumental in mechanism discovery and in validation of treatment targets and therapies. 5 Recent advances in the development of such models-in particular, in the establishment of genetically engineered models-have
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Ideally, experimental models should reproduce all of these histopathologic characteristics and should closely resemble human gliomas in their genetic and epigenetic profiles. Depending on the focus of the investigation, several additional requirements may arise.
To ensure an undisrupted microenvironment with an intact bloodbrain barrier (BBB) and immune response, studies on prevention and early detection of glioma would ideally be performed with spontaneous models, or at least with models that avoid physical manipulation of the brain. At the same time, the models should show a penetrance sufficient to allow evaluation of statistical significance.
Studies focused on treatment should be performed with models that replicate the heterogeneity of human tumors, given that oversimplification with the use of a single type of cell or genetic aberration might yield results that are misleading with regard to drug efficacy and lead to failure of clinical studies. 8 Furthermore, the requirements regarding the microenvironment also apply to treatment studies.
Tumor formation must be highly reproducible and tumor penetrance and latency should also be adequate for assessment of treatment effects.
Even if a single preclinical model of malignant glioma could fulfill all of these conditions necessary to mimic human disease, researchers would still have to adjust for species and strain differences, making validation in several models necessary. To date, available models can be classified into spontaneous, chemically induced, genetically engineered, and transplantation categories, with each type of model being best suited to investigate specific aspects of disease evolution ( Figure 1 , Table 1 ).
| Spontaneous gliomas
Extensive research on brain scrapie with the use of 23 inbred mouse strains led to the discovery that astrocytomas occur with the highest frequency among spontaneous neuroectodermal tumors and that they recapitulate human glioma characteristics such as spread along white matter tracts. 9 However, their development was found to be 
| Chemically induced models
The administration of carcinogens to initiate intracranial neoplasms represents one of the earliest types of induced glioma model. This approach, used to achieve conditional inactivation of tumor suppressors p53, Nf1 and Pten, also generates grade III or IV gliomas with a high penetrance. a large variety of studies, ranging from testing the oncogenic potential of various genetic aberrations to elucidation of the molecular characteristics of glioma stem cells. [20] [21] [22] Finally, genome editing technologies have recently started to provide new opportunities in cancer modeling. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system can be applied to mouse zygotes to generate animals that harbor the targeted genetic modifications. A detailed protocol for generating mouse models with this system has been described. 23 This versatile technology can produce knockout, mutant, tagged or other targeted alleles in the mouse and might therefore become a preferred choice for cancer modeling in the future. 24 In utero electroporation of the ventricular zone in the cerebrum of wild-type mice at embryonic day 13.5 to achieve the simultaneous delivery of three plasmids encoding Cas9 as well as guide RNAs targeting 
| Cell of origin
Given the histological and molecular heterogeneity of malignant gliomas, it is possible that, by the time of treatment, the cell of origin is no longer present or does not constitute the most therapy-resistant clone in the tumor. 37 However, the ability to unequivocally identify the cells that initiate gliomas not only will deepen our understanding of this malignancy but also might lead to the discovery of molecular markers useful for early diagnosis.
There has been much speculation regarding the differentiation sta- With the use of mice deficient for p16
Ink4a
, p19 Arf or both, Bachoo and colleagues showed that loss of both p16 Ink4a and p19 Arf is sufficient for dedifferentiation of astrocytes in serum-free culture and also renders these cells susceptible to transformation by a constitutively active mutant of EGFR (VIIEGFR). In contrast, loss of p16
, p19
Arf , or Tp53 alone was not sufficient for astrocyte dedifferentiation. 38 Uhrbom et al 39 
| Invasion
Seminal pathology studies showed that gliomas undergo diffuse infiltration into the surrounding brain, manifesting several invasion patterns: perineuronal, perivascular, subpial, and along myelinated fibers. 44 also provided insight into the relation between invasive phenotypes and molecular and epigenetic regulators. 45, 46 Furthermore, as with regard to the cell of origin, the combination of new models, visualization at single-cell resolution, and the switch to growth factor-based culture has led to the discovery of novel invasion characteristics. well, 55 and the development of humanized mice 56 will likely be adapted to recapitulate populations of immune cells present in the brain. Finally, GEMMs in combination with clinical trials will be instrumental in the fine-tuning of therapy, 57, 58 and the models will be further advanced at the same time by feedback from such trials. 
